ChinaDaily Briefs

Daily Brief China: Wharf Holdings, Activision Blizzard, Brilliance China Automotive, Growatt Technology, Haier Smart Home Co Ltd, Jiangsu Expressway (H), Hutchison China MediTech Ltd, Sino-Ocean Group and more

In today’s briefing:

  • Wharf Holdings (4 HK): MSCI Deletion, Short Interest & Trade Ideas
  • China Internet Weekly (14Nov2022): NetEase, Activision Blizzard, Alibaba, Tencent, IQiyi, Suning.com
  • HSCI Index Rebalance and Stock Connect: Changes at the Margins
  • Growatt Technology Pre-IPO Peer Comparison – Performed Well on Many Fronts
  • Back in Hong Kong stocks
  • Jiangsu Expressway (177 HK): Positive Updates from Management
  • Hutchison China MediTech (HCM.US/13.HK) – The Pain Points Become More Pronounced
  • Morning Views Asia: NagaCorp Ltd, Sino-Ocean Service

Wharf Holdings (4 HK): MSCI Deletion, Short Interest & Trade Ideas

By Brian Freitas

  • In a surprise, MSCI announced the deletion of Wharf Holdings (4 HK) from the MSCI China Index at the November SAIR that will be implemented at the close 30 November.
  • The stock dropped 14.3% on Friday as volume spiked 26x compared to ADV and 14m shares were shorted on the day.
  • Total short interest is estimated to be significantly lower than the estimated selling from passive MSCI trackers and there could be a move lower over the next few days.

China Internet Weekly (14Nov2022): NetEase, Activision Blizzard, Alibaba, Tencent, IQiyi, Suning.com

By Ming Lu

  • NetEase and Activision Blizzard will possibly terminate their cooperation next January.
  • Singles’ Day sales were not very successful for e-commerce apps such as Alibaba and JD.com.
  • IQiyi announced a revenue share rule to short TV series producers, including cost per mille and membership fee.

HSCI Index Rebalance and Stock Connect: Changes at the Margins

By Brian Freitas

  • We see 3 potential adds for the HSCI in December. We also see 26 potential adds and 16 potential deletes for the index in March.
  • Following the March rebalance, we see 22 potential inclusions to Stock Connect while we expect 37 stocks to be removed from the link.
  • Some of the potential deletions/ Stock Connect drops have large Southbound holdings and some of these positions could be pared back over the next few months.

Growatt Technology Pre-IPO Peer Comparison – Performed Well on Many Fronts

By Ethan Aw

  • Growatt Technology (1833969D CH) is looking to raise about US$500m in its upcoming Hong Kong IPO. 
  • Growatt Technology is a global distributed energy solution provider, specializing in sustainable energy generation, storage and consumption, as well as energy digitalization. 
  • In our previous notes, we looked at the company’s past performance. In this note, we undertake a peer comparison.

Back in Hong Kong stocks

By Turtles all the way down

  • Early this year I was quite pessimistic on Hong Kong stocks.
  • But since then the Hang Seng is down another 20% or so. A lot of stocks with 9-10%+ dividend yields are laying around.
  • I should have been a bit quicker writing this up, but then you are getting it for free.

Jiangsu Expressway (177 HK): Positive Updates from Management

By Osbert Tang, CFA

  • Jiangsu Expressway (H) (177 HK) has seen marginally weaker traffic in 4Q22 relative to 3Q22 due to sporadic COVID outbreaks but the magnitude is manageable. 
  • We welcome its indication that stable absolute DPS level will be maintained, with additional target to increase gradually. That means secured FY22 and FY23 yield of at least 8.3%.
  • Clean energy investment and exit of property business will improve earnings quality. Projected ROE of over 13% also provides good justification for upside to its 0.8x P/B. 

Hutchison China MediTech (HCM.US/13.HK) – The Pain Points Become More Pronounced

By Xinyao (Criss) Wang

  • Hutchison China MediTech Ltd (HCM US) (Hutchmed) didn’t perform well. Its cash holdings could last about two and a half years considering the cash burn rate.
  • Hutchmed’s three major commercialized products would all face different challenges. Feedbacks from FDA/MAA cast a shadow on the Company’s internationalization prospects. 
  • According to the current speed of pharmaceutical innovation, Hutchmed’s R&D efficiency/productivity is not satisfactory. The current pipeline does not have core competitiveness. Bearish on outlook.

Morning Views Asia: NagaCorp Ltd, Sino-Ocean Service

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars